FDA Nominee Heidi Overton Faces Senate Scrutiny Over Abortion Pill, Vaccine Claims and Vaping Rules

WASHINGTON — President Donald Trump’s nominee to lead the Food and Drug Administration, Dr. Heidi Overton, is set to appear before the Senate health committee Thursday and is expected to face sharp questions about her views on vaccines, the abortion pill mifepristone and new rules for flavored electronic cigarettes.

Background and Key Concerns

Dr. Overton, a physician and senior White House aide, has spent much of her career working for Trump or conservative organizations that align with his policy agenda. In her current role as a domestic policy adviser, she helped craft White House health initiatives including revisions to federal dietary guidance and proposals to change how childhood vaccinations are scheduled. She previously served as an executive at the America First Policy Institute, where she authored critiques of abortion access and transgender medical care.

If confirmed, Overton would inherit several contentious items at the FDA: an ongoing safety review of mifepristone, a proposal to separate combination vaccines into individual doses, and draft rules that could make it easier to market flavored e-cigarettes. All three would represent departures from long-standing FDA positions, particularly on the safety and administration of childhood vaccines.

Sen. Bill Cassidy, the Louisiana physician who chairs the health committee, described Overton's support for spacing out vaccines as 'almost disqualifying.'

Controversies and Statements

Last month, Overton stood with President Trump and Health Secretary Robert F. Kennedy in the Oval Office when they suggested — contrary to scientific consensus — that combination vaccines could contribute to autism. Overton has also criticized the FDA's 2023 decision to permit mail delivery of mifepristone, calling the policy 'chemical abortion on demand' while at the America First Policy Institute. She has spoken out against access to puberty blockers and gender-affirming surgery for minors and co-wrote a polemical 2024 article about Minnesota politics that used inflammatory language about abortion and transgender care.

Confirmation Outlook and Agency Challenges

Overton's positions may complicate efforts to win support from moderate Republicans on the committee, including Sen. Susan Collins of Maine and Sen. Lisa Murkowski of Alaska, both of whom have at times supported federal protections for abortion access. To be confirmed, she must first secure a majority among the 21-member Senate health committee and then a favorable vote in the full Senate.

The FDA, headquartered in the Washington suburbs, oversees medical products and large portions of the nation's food, cosmetics, tobacco and vaping markets. The agency employs roughly 16,000 people and has lost about 20% of its workforce since the current administration began, through layoffs, buyouts, retirements and resignations. The previous commissioner, Dr. Marty Makary, resigned in May after a tenure marked by public scientific disputes and internal turnover; Overton studied under Makary at Johns Hopkins, where she earned a doctoral degree in clinical research after receiving her medical degree from the University of New Mexico.

Unlike some recent nominees, Overton reported no investments in health-care or food companies in her financial disclosures. She listed student loan obligations in the range of $50,000 to $100,000.

What Comes Next: The Senate hearing will probe how Overton would balance the administration's pushes to loosen regulation in some areas, like vaping, with efforts by others in the administration to increase scrutiny of vaccines, drugs and food ingredients. Lawmakers will also press her on the scientific basis for any proposed changes and on the management experience needed to lead a large, highly technical regulatory agency.